Full Press Release Details
dupixent dupilumab positive phase 3 data in children 1 to 11 years of age with eosinophilic esophagitis published in the new england journal of medicine.
REGN
dupixent dupilumab positive phase 3 data in children 1 to 11 years of age with eosinophilic esophagitis published in the new england journal of medicine
Key Takeaway: dupixent dupilumab positive phase 3 data in children 1 to 11 years of age with eosinophilic esophagitis published in the new england journal of medicine